A startup developing treatments for eye diseases has raised $330 million from investors as it readies for late-stage testing.

One of the year’s largest venture funding rounds comes just after a head-to-head study showed Ollin’s drug — licensed from a China-based developer — had certain advantages over…

A startup developing treatments for eye diseases has raised $330 million from investors as it readies for late-stage testing.